정신분열병 환자에서 항정신병 약물과 항불안제 병합치료의 효과

• 영문명: Effect of Antianxiety Drug Augmentation in the Neuroleptics Treated Schizophrenia Patients
• 발행기관: 대한신경정신의학회
• 저자명: 임원정 우행원
• 간행물 정보: 『신경정신의학』제32권 제6호, 971~982쪽, 전체 12쪽
• 주제분류: 의약학 > 정신과학
• 파일형태: PDF
• 발행일자: 1993.11.30

영문 초록

Among the psychiatric patients, 60% of them suffer from schizophrenia. Psychopharmacological approach is the most important therapy for schizophrenic patients, however there is some limitation in psychotropic drugs usage. It is well known by now that hyperdopaminergic theory is the most reliable etiology of schizophrenia, but there is also another theory that hypofunction of GAEACy-aminobutyric acid) can be an etiology of schizophrenia. Therefore the author intend to prove clinical and biological changes by applying GABA agonist alprazolam augmentation therapy in schizophre- The subjects were 30 schizophrenic inpatients who met DSM-III-R criteria for schizophrenia. Symptom Checklist 90 Revised and positive & negative syndrome scale (PANSS) were used as clinical index ans 3 1/2 hours urine HVA level was used as biological index. These clinical and biological tests were performed before and after alprazolam augmentation therapy with at least 2 weeks interval. The differences between before and after alprazolam augmentation were as follow : 1) After alprazolam augmentation, anxiety scores, psychoticism score, and paranoid tendncy score of SCL-90-R were significantly reduced(P<0.05). Positive symptom scale socres of PANSS(p<0.01) and general psychopathy scale score(p〈0. 05) were significantly reduced. Negative symptom scale scores of PANSS were reduced but not statistacally significant. 2) Urine HVA levels were not significantly changed in the total patient group. But the urine HVA level in the higher HVA group (〉1.6mg/3.5hr) was significantly reduced(p

목차

서 론

연구대상 및 방법

결 과

고 찰

결 론

References

키워드

Schizophrenia Neuroleptics Alprazolam SCL-90-R PANSS HVA

참고문헌